BIOLASE (NASDAQ:BIOL) Stock Rating Lowered by Zacks Investment Research

BIOLASE (NASDAQ:BIOL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “Biolaw Technology, Inc. is the world’s leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets. “

Other research analysts have also recently issued research reports about the stock. Benchmark initiated coverage on shares of BIOLASE in a research note on Wednesday, June 19th. They issued a “speculative buy” rating and a $2.00 target price for the company. ValuEngine cut shares of BIOLASE from a “buy” rating to a “hold” rating in a research note on Thursday, September 26th. Finally, Ascendiant Capital Markets set a $3.00 target price on shares of BIOLASE and gave the company a “buy” rating in a research note on Monday, August 12th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. BIOLASE currently has an average rating of “Buy” and an average price target of $2.17.



Shares of NASDAQ:BIOL remained flat at $$0.79 during trading on Wednesday. 47,370 shares of the stock were exchanged, compared to its average volume of 41,663. BIOLASE has a 52 week low of $0.76 and a 52 week high of $2.87. The firm has a 50 day simple moving average of $1.02 and a 200-day simple moving average of $1.63. The company has a debt-to-equity ratio of 3.51, a current ratio of 2.04 and a quick ratio of 1.11. The company has a market cap of $17.31 million, a PE ratio of -0.93 and a beta of 2.25.

BIOLASE (NASDAQ:BIOL) last posted its earnings results on Thursday, August 8th. The medical technology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.03. BIOLASE had a negative net margin of 47.46% and a negative return on equity of 159.26%. The company had revenue of $8.65 million during the quarter, compared to analysts’ expectations of $12.76 million. Equities research analysts anticipate that BIOLASE will post -0.59 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in BIOLASE stock. BlackRock Inc. lifted its stake in BIOLASE Inc (NASDAQ:BIOL) by 3.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 298,875 shares of the medical technology company’s stock after purchasing an additional 9,698 shares during the period. BlackRock Inc. owned 1.40% of BIOLASE worth $440,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 37.80% of the company’s stock.

About BIOLASE

BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on BIOLASE (BIOL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.